Share Price and Basic Stock Data
Last Updated: October 8, 2025, 10:44 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Achyut Healthcare Ltd, operating in the pharmaceutical industry, has a market capitalization of ₹145 Cr. The company has shown resilience in sales, with a Net Profit of ₹0.55 Cr. However, the Operating Profit Margin (OPM) stands at -13.04%, indicating a need for cost management. The quarterly and annual sales trends depict a steady revenue stream, but expenses seem to be impacting profitability.
Profitability and Efficiency Metrics
With a Price-to-Earnings (P/E) ratio of 264, Achyut Healthcare faces challenges in translating sales into profits efficiently. The Return on Equity (ROE) at 1.77% and Return on Capital Employed (ROCE) at 2.26% reflect low profitability and inefficient capital utilization. The Interest Coverage Ratio (ICR) of 3596.50x indicates a strong ability to service debt. However, the Cash Conversion Cycle (CCC) of 40.81 days suggests a longer cash tied-up period impacting liquidity.
Balance Sheet Strength and Financial Ratios
Achyut Healthcare’s reserves stand at ₹7.74 Cr, indicating a moderate financial cushion. The absence of borrowings signifies a debt-free status, enhancing solvency. The Price-to-Book Value (P/BV) ratio of 2.45x suggests the stock might be overvalued concerning its book value. The company’s Interest Coverage Ratio (ICR) indicates robust debt-servicing capabilities, but liquidity ratios need monitoring for optimal working capital management.
Shareholding Pattern and Investor Confidence
Promoters hold a significant stake at 46.37%, indicating a vested interest in the company’s performance. Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) hold 6.14% and N/A %, respectively, showcasing moderate institutional interest. Public shareholding at 47.49% signifies retail investor participation. Changes in promoter holdings can impact investor confidence and stock valuation, necessitating a close watch on these trends.
Outlook, Risks, and Final Insight
Looking ahead, Achyut Healthcare’s growth prospects hinge on enhancing operational efficiency and profitability. Key drivers could include expanding market reach and optimizing cost structures. Risks such as regulatory challenges and intense competition may pose threats to future performance. Strengthening financial ratios and improving investor confidence through transparent communication and strategic initiatives will be crucial for the company’s sustained success in the dynamic pharmaceutical sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Achyut Healthcare Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 152 Cr. | 121 | 247/84.3 | 34.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.98 Cr. | 2.08 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,528 Cr. | 415 | 434/192 | 102 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.3 Cr. | 42.2 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 29.3 Cr. | 20.0 | 29.1/17.0 | 30.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 18,996.63 Cr | 1,173.56 | 51.08 | 192.71 | 0.33% | 16.15% | 14.90% | 6.18 |
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2.71 | 1.34 | 1.89 | 0.81 | 1.48 | 4.65 | 2.13 | 0.92 |
| Expenses | 2.56 | 1.53 | 1.87 | 1.10 | 1.45 | 4.66 | 2.21 | 1.04 |
| Operating Profit | 0.15 | -0.19 | 0.02 | -0.29 | 0.03 | -0.01 | -0.08 | -0.12 |
| OPM % | 5.54% | -14.18% | 1.06% | -35.80% | 2.03% | -0.22% | -3.76% | -13.04% |
| Other Income | 0.02 | 0.13 | 0.23 | 0.36 | 0.32 | 0.41 | 0.56 | 0.36 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Profit before tax | 0.17 | -0.07 | 0.25 | 0.07 | 0.35 | 0.40 | 0.47 | 0.24 |
| Tax % | 47.06% | -28.57% | 0.00% | 114.29% | 22.86% | 20.00% | 25.53% | 16.67% |
| Net Profit | 0.09 | -0.05 | 0.24 | -0.01 | 0.26 | 0.31 | 0.35 | 0.20 |
| EPS in Rs | 0.01 | -0.00 | 0.02 | -0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
Last Updated: May 31, 2025, 7:11 am
Below is a detailed analysis of the quarterly data for Achyut Healthcare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 0.92 Cr.. The value appears to be declining and may need further review. It has decreased from 2.13 Cr. (Sep 2024) to 0.92 Cr., marking a decrease of 1.21 Cr..
- For Expenses, as of Mar 2025, the value is 1.04 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.21 Cr. (Sep 2024) to 1.04 Cr., marking a decrease of 1.17 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.12 Cr.. The value appears to be declining and may need further review. It has decreased from -0.08 Cr. (Sep 2024) to -0.12 Cr., marking a decrease of 0.04 Cr..
- For OPM %, as of Mar 2025, the value is -13.04%. The value appears to be declining and may need further review. It has decreased from -3.76% (Sep 2024) to -13.04%, marking a decrease of 9.28%.
- For Other Income, as of Mar 2025, the value is 0.36 Cr.. The value appears to be declining and may need further review. It has decreased from 0.56 Cr. (Sep 2024) to 0.36 Cr., marking a decrease of 0.20 Cr..
- For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.01 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.24 Cr.. The value appears to be declining and may need further review. It has decreased from 0.47 Cr. (Sep 2024) to 0.24 Cr., marking a decrease of 0.23 Cr..
- For Tax %, as of Mar 2025, the value is 16.67%. The value appears to be improving (decreasing) as expected. It has decreased from 25.53% (Sep 2024) to 16.67%, marking a decrease of 8.86%.
- For Net Profit, as of Mar 2025, the value is 0.20 Cr.. The value appears to be declining and may need further review. It has decreased from 0.35 Cr. (Sep 2024) to 0.20 Cr., marking a decrease of 0.15 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.01. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 3:17 pm
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 0.67 | 0.33 | 0.27 | 4.05 | 2.70 | 6.14 | 3.05 |
| Expenses | 0.66 | 0.32 | 0.26 | 4.08 | 2.97 | 6.12 | 3.25 |
| Operating Profit | 0.01 | 0.01 | 0.01 | -0.03 | -0.27 | 0.02 | -0.20 |
| OPM % | 1.49% | 3.03% | 3.70% | -0.74% | -10.00% | 0.33% | -6.56% |
| Other Income | 0.00 | 0.01 | 0.00 | 0.14 | 0.59 | 0.73 | 0.92 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 |
| Profit before tax | 0.01 | 0.02 | 0.01 | 0.10 | 0.31 | 0.74 | 0.70 |
| Tax % | 300.00% | 0.00% | 0.00% | 60.00% | 25.81% | 22.97% | 22.86% |
| Net Profit | -0.01 | 0.01 | 0.01 | 0.04 | 0.23 | 0.57 | 0.55 |
| EPS in Rs | -0.02 | 0.02 | 0.02 | 0.00 | 0.01 | 0.02 | 0.02 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 200.00% | 0.00% | 300.00% | 475.00% | 147.83% | -3.51% |
| Change in YoY Net Profit Growth (%) | 0.00% | -200.00% | 300.00% | 175.00% | -327.17% | -151.33% |
Achyut Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 56% |
| 3 Years: | -9% |
| TTM: | -50% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 123% |
| 3 Years: | 140% |
| TTM: | -4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 88% |
| 1 Year: | 44% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: July 25, 2025, 2:00 pm
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 0.25 | 6.74 | 9.35 | 16.83 | 23.56 |
| Reserves | -0.05 | -0.04 | 0.00 | 2.34 | 5.18 | 13.93 | 7.74 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.04 | 0.06 | 0.25 | 0.86 | 0.81 | 0.19 | 1.29 |
| Total Liabilities | 0.24 | 0.27 | 0.50 | 9.94 | 15.34 | 30.95 | 32.59 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.03 | 0.05 | 0.06 | 0.03 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 3.49 | 9.16 | 18.19 |
| Investments | 0.00 | 0.00 | 0.00 | 1.70 | 1.30 | 0.00 | 0.00 |
| Other Assets | 0.24 | 0.27 | 0.50 | 8.21 | 10.50 | 21.73 | 14.37 |
| Total Assets | 0.24 | 0.27 | 0.50 | 9.94 | 15.34 | 30.95 | 32.59 |
Below is a detailed analysis of the balance sheet data for Achyut Healthcare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 23.56 Cr.. The value appears strong and on an upward trend. It has increased from 16.83 Cr. (Mar 2024) to 23.56 Cr., marking an increase of 6.73 Cr..
- For Reserves, as of Mar 2025, the value is 7.74 Cr.. The value appears to be declining and may need further review. It has decreased from 13.93 Cr. (Mar 2024) to 7.74 Cr., marking a decrease of 6.19 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 1.29 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.19 Cr. (Mar 2024) to 1.29 Cr., marking an increase of 1.10 Cr..
- For Total Liabilities, as of Mar 2025, the value is 32.59 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 30.95 Cr. (Mar 2024) to 32.59 Cr., marking an increase of 1.64 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.03 Cr.. The value appears to be declining and may need further review. It has decreased from 0.06 Cr. (Mar 2024) to 0.03 Cr., marking a decrease of 0.03 Cr..
- For CWIP, as of Mar 2025, the value is 18.19 Cr.. The value appears strong and on an upward trend. It has increased from 9.16 Cr. (Mar 2024) to 18.19 Cr., marking an increase of 9.03 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 14.37 Cr.. The value appears to be declining and may need further review. It has decreased from 21.73 Cr. (Mar 2024) to 14.37 Cr., marking a decrease of 7.36 Cr..
- For Total Assets, as of Mar 2025, the value is 32.59 Cr.. The value appears strong and on an upward trend. It has increased from 30.95 Cr. (Mar 2024) to 32.59 Cr., marking an increase of 1.64 Cr..
Notably, the Reserves (7.74 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.01 | 0.01 | 0.01 | -0.03 | -0.27 | 0.02 | -0.20 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 54.48 | 188.03 | 378.52 | 18.02 | 36.50 | 24.37 | 160.36 |
| Inventory Days | 0.00 | 0.00 | 158.70 | 14.29 | 59.59 | 3.96 | 24.16 |
| Days Payable | 380.87 | 41.78 | 55.87 | 12.54 | 143.71 | ||
| Cash Conversion Cycle | 54.48 | 188.03 | 156.34 | -9.46 | 40.22 | 15.79 | 40.81 |
| Working Capital Days | 76.27 | 210.15 | 216.30 | 603.83 | 1,257.22 | 1,242.43 | 1,169.20 |
| ROCE % | 9.76% | 4.35% | 2.14% | 2.63% | 3.27% | 2.26% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.02 | 0.34 | 0.31 | 0.15 | 0.30 |
| Diluted EPS (Rs.) | 0.02 | 0.34 | 0.31 | 0.15 | 0.30 |
| Cash EPS (Rs.) | 0.02 | 0.34 | 0.25 | 0.06 | 0.29 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.33 | 18.28 | 15.54 | 13.48 | 8.68 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.33 | 18.28 | 15.54 | 13.48 | 8.68 |
| Revenue From Operations / Share (Rs.) | 0.12 | 3.65 | 2.88 | 6.01 | 10.91 |
| PBDIT / Share (Rs.) | 0.03 | 0.44 | 0.33 | 0.15 | 0.42 |
| PBIT / Share (Rs.) | 0.02 | 0.44 | 0.33 | 0.15 | 0.42 |
| PBT / Share (Rs.) | 0.02 | 0.44 | 0.33 | 0.14 | 0.40 |
| Net Profit / Share (Rs.) | 0.02 | 0.34 | 0.24 | 0.05 | 0.29 |
| PBDIT Margin (%) | 23.60 | 12.24 | 11.78 | 2.62 | 3.85 |
| PBIT Margin (%) | 23.09 | 12.11 | 11.54 | 2.49 | 3.85 |
| PBT Margin (%) | 23.08 | 12.07 | 11.48 | 2.48 | 3.74 |
| Net Profit Margin (%) | 17.97 | 9.34 | 8.57 | 0.99 | 2.71 |
| Return on Networth / Equity (%) | 1.74 | 1.86 | 1.59 | 0.44 | 3.41 |
| Return on Capital Employeed (%) | 2.24 | 2.41 | 2.14 | 1.11 | 4.83 |
| Return On Assets (%) | 1.68 | 1.85 | 1.50 | 0.40 | 1.57 |
| Asset Turnover Ratio (%) | 0.09 | 0.26 | 0.21 | 0.77 | 0.73 |
| Current Ratio (X) | 9.32 | 106.66 | 12.68 | 9.46 | 1.82 |
| Quick Ratio (X) | 9.18 | 106.38 | 12.29 | 9.31 | 1.44 |
| Interest Coverage Ratio (X) | 3596.50 | 375.85 | 186.88 | 169.54 | 35.00 |
| Interest Coverage Ratio (Post Tax) (X) | 2739.50 | 287.60 | 137.00 | 65.14 | 25.67 |
| Enterprise Value (Cr.) | 75.79 | 87.10 | 50.86 | 13.59 | 0.00 |
| EV / Net Operating Revenue (X) | 24.87 | 14.19 | 18.87 | 3.36 | 0.00 |
| EV / EBITDA (X) | 105.37 | 115.87 | 160.10 | 127.69 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 25.20 | 14.25 | 18.96 | 3.42 | 0.00 |
| Price / BV (X) | 2.45 | 2.84 | 3.52 | 1.52 | 0.00 |
| Price / Net Operating Revenue (X) | 25.21 | 14.26 | 18.96 | 3.42 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
After reviewing the key financial ratios for Achyut Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 1.00, marking a decrease of 9.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.34 (Mar 24) to 0.02, marking a decrease of 0.32.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.34 (Mar 24) to 0.02, marking a decrease of 0.32.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 3. It has decreased from 0.34 (Mar 24) to 0.02, marking a decrease of 0.32.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.33. It has decreased from 18.28 (Mar 24) to 1.33, marking a decrease of 16.95.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.33. It has decreased from 18.28 (Mar 24) to 1.33, marking a decrease of 16.95.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.12. It has decreased from 3.65 (Mar 24) to 0.12, marking a decrease of 3.53.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 2. It has decreased from 0.44 (Mar 24) to 0.03, marking a decrease of 0.41.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.02, marking a decrease of 0.42.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.02, marking a decrease of 0.42.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 2. It has decreased from 0.34 (Mar 24) to 0.02, marking a decrease of 0.32.
- For PBDIT Margin (%), as of Mar 25, the value is 23.60. This value is within the healthy range. It has increased from 12.24 (Mar 24) to 23.60, marking an increase of 11.36.
- For PBIT Margin (%), as of Mar 25, the value is 23.09. This value exceeds the healthy maximum of 20. It has increased from 12.11 (Mar 24) to 23.09, marking an increase of 10.98.
- For PBT Margin (%), as of Mar 25, the value is 23.08. This value is within the healthy range. It has increased from 12.07 (Mar 24) to 23.08, marking an increase of 11.01.
- For Net Profit Margin (%), as of Mar 25, the value is 17.97. This value exceeds the healthy maximum of 10. It has increased from 9.34 (Mar 24) to 17.97, marking an increase of 8.63.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.74. This value is below the healthy minimum of 15. It has decreased from 1.86 (Mar 24) to 1.74, marking a decrease of 0.12.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.24. This value is below the healthy minimum of 10. It has decreased from 2.41 (Mar 24) to 2.24, marking a decrease of 0.17.
- For Return On Assets (%), as of Mar 25, the value is 1.68. This value is below the healthy minimum of 5. It has decreased from 1.85 (Mar 24) to 1.68, marking a decrease of 0.17.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.09. It has decreased from 0.26 (Mar 24) to 0.09, marking a decrease of 0.17.
- For Current Ratio (X), as of Mar 25, the value is 9.32. This value exceeds the healthy maximum of 3. It has decreased from 106.66 (Mar 24) to 9.32, marking a decrease of 97.34.
- For Quick Ratio (X), as of Mar 25, the value is 9.18. This value exceeds the healthy maximum of 2. It has decreased from 106.38 (Mar 24) to 9.18, marking a decrease of 97.20.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3,596.50. This value is within the healthy range. It has increased from 375.85 (Mar 24) to 3,596.50, marking an increase of 3,220.65.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2,739.50. This value is within the healthy range. It has increased from 287.60 (Mar 24) to 2,739.50, marking an increase of 2,451.90.
- For Enterprise Value (Cr.), as of Mar 25, the value is 75.79. It has decreased from 87.10 (Mar 24) to 75.79, marking a decrease of 11.31.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 24.87. This value exceeds the healthy maximum of 3. It has increased from 14.19 (Mar 24) to 24.87, marking an increase of 10.68.
- For EV / EBITDA (X), as of Mar 25, the value is 105.37. This value exceeds the healthy maximum of 15. It has decreased from 115.87 (Mar 24) to 105.37, marking a decrease of 10.50.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 25.20. This value exceeds the healthy maximum of 3. It has increased from 14.25 (Mar 24) to 25.20, marking an increase of 10.95.
- For Price / BV (X), as of Mar 25, the value is 2.45. This value is within the healthy range. It has decreased from 2.84 (Mar 24) to 2.45, marking a decrease of 0.39.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 25.21. This value exceeds the healthy maximum of 3. It has increased from 14.26 (Mar 24) to 25.21, marking an increase of 10.95.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Achyut Healthcare Ltd:
- Net Profit Margin: 17.97%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.24% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.74% (Industry Average ROE: 14.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2739.5
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 9.18
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 259 (Industry average Stock P/E: 51.08)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.97%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 610, Colonade, B/H Iscon Temple, Opposite Iscon, BRTS Bus Stand, Ahmedabad Gujarat 380058 | mahendrazenith@hotmail.com http://www.achyuthealthcare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mahendra Chatrabhuj Raycha | Chairman & Non-Exe.Director |
| Mr. Jigen Jagdishbhai Modi | Managing Director |
| Ms. Amisha Jigen Modi | Executive Director |
| Mr. Akshit Mahendra Raycha | Non Executive Director |
| Mr. Rutvik Sanjaykumar Thakkar | Independent Director |
| Mrs. Sonu Lalitkumar Jain | Independent Director |
FAQ
What is the intrinsic value of Achyut Healthcare Ltd?
Achyut Healthcare Ltd's intrinsic value (as of 10 October 2025) is 4.98 which is 17.69% lower the current market price of 6.05, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹143 Cr. market cap, FY2025-2026 high/low of 6.57/2.82, reserves of ₹7.74 Cr, and liabilities of 32.59 Cr.
What is the Market Cap of Achyut Healthcare Ltd?
The Market Cap of Achyut Healthcare Ltd is 143 Cr..
What is the current Stock Price of Achyut Healthcare Ltd as on 10 October 2025?
The current stock price of Achyut Healthcare Ltd as on 10 October 2025 is 6.05.
What is the High / Low of Achyut Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Achyut Healthcare Ltd stocks is 6.57/2.82.
What is the Stock P/E of Achyut Healthcare Ltd?
The Stock P/E of Achyut Healthcare Ltd is 259.
What is the Book Value of Achyut Healthcare Ltd?
The Book Value of Achyut Healthcare Ltd is 1.33.
What is the Dividend Yield of Achyut Healthcare Ltd?
The Dividend Yield of Achyut Healthcare Ltd is 0.00 %.
What is the ROCE of Achyut Healthcare Ltd?
The ROCE of Achyut Healthcare Ltd is 2.26 %.
What is the ROE of Achyut Healthcare Ltd?
The ROE of Achyut Healthcare Ltd is 1.77 %.
What is the Face Value of Achyut Healthcare Ltd?
The Face Value of Achyut Healthcare Ltd is 1.00.